Strategic partnerships Mirimus has a history of collaborating with major biopharma and academic partners (Biogen, St. John’s University, Eckerd College, Yale) for diagnostic testing and research model development, signaling appetite for co-development opportunities and expanded services.

PCR testing leadership The company positions as a leader in high-volume, high-quality PCR testing and SalivaClear pooled testing, suggesting strong capabilities to support client-scale diagnostic programs and mass surveillance initiatives.

RNAi and CRISPR focus Core competencies in RNAi and CRISPR-based model creation indicate upsell opportunities for drug discovery services, target validation, and generation of customized in vivo and in vitro models for pharma pipelines.

Global health emphasis A stated commitment to global health equity and affordable technologies presents a storytelling angle for partnerships with NGOs, public health programs, and government-funded initiatives seeking scalable diagnostic and therapeutic solutions.

Diversified tech stack Leveraging cloud and analytics tools (AWS, HubSpot, Webflow) and digital platforms signals readiness for expanding customer-facing digital offerings, customer success programs, and streamlined collaboration with enterprise partners.